{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:19:37Z","timestamp":1791821977178,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10384-022-00922-3","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T03:37:26Z","timestamp":1653104246000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Short-term results for brolucizumab in treatment-na\u00efve neovascular age-related macular degeneration: a Japanese multicenter study"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3323-4148","authenticated-orcid":false,"given":"Koji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorako","family":"Wakugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shintake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruka","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusaburo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"922_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116\u201326.","journal-title":"Ophthalmology"},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559\u201369.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"922_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Egh\u00f8j","year":"2012","unstructured":"Egh\u00f8j MS, S\u00f8rensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96:21\u20133.","journal-title":"Br J Ophthalmol"},{"key":"922_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92567-4","volume":"11","author":"S Honda","year":"2021","unstructured":"Honda S, Yanagi Y, Koizumi H, Chen Y, Tanaka S, Arimoto M, et al. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11: 13152.","journal-title":"Sci Rep"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, HAWK and HARRIER Study Investigators, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: Ninety-six-week outcomes from the Phase 3 trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"MA Brolucizumab","year":"2019","unstructured":"Brolucizumab MA. First approval. Drugs. 2019;79:1997\u20132000.","journal-title":"Drugs"},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4:269\u201379.","journal-title":"J Vitreoretin Dis"},{"key":"922_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345\u201359.","journal-title":"Ophthalmology"},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1\u201310.","journal-title":"Ophthalmology"},{"key":"922_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","volume":"6","author":"M Singer","year":"2021","unstructured":"Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2021;6:97\u2013108.","journal-title":"Ophthalmol Retina"},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10384-021-00819-7","volume":"65","author":"T Hikichi","year":"2021","unstructured":"Hikichi T. 3 Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn J Ophthalmol. 2021;65:208\u201314.","journal-title":"Jpn J Ophthalmol"},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","volume":"65","author":"K Kataoka","year":"2021","unstructured":"Kataoka K, Horiguchi E, Kawano K, Ushida H, Nakano Y, Ito Y, et al. 3 cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. Jpn J Ophthalmol. 2021;65:199\u2013207.","journal-title":"Jpn J Ophthalmol"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","volume":"259","author":"I Maruko","year":"2021","unstructured":"Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Japan AMD Research Consortium, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259:2857\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","volume":"139","author":"AB Enr\u00edquez","year":"2021","unstructured":"Enr\u00edquez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139:441\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"922_CR16","doi-asserted-by":"crossref","unstructured":"Bulirsch LM, Sa\u00dfmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021; bjophthalmol-2020-318672.","DOI":"10.1136\/bjophthalmol-2020-318672"},{"key":"922_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11:1\u20138.","journal-title":"Sci Rep"},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"922_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","volume":"15","author":"RF Spaide","year":"1995","unstructured":"Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100\u201310.","journal-title":"Retina"},{"key":"922_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negr\u00e3o S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416\u201334.","journal-title":"Retina"},{"key":"922_CR21","doi-asserted-by":"crossref","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2021: bjophthalmol-2021-319090.","DOI":"10.1136\/bjophthalmol-2021-319090"},{"key":"922_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:627\u201333.","journal-title":"Am J Ophthalmol"},{"key":"922_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1167\/iovs.04-1051","volume":"46","author":"L Pitk\u00e4nen","year":"2005","unstructured":"Pitk\u00e4nen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Investig Ophthalmol Vis Sci. 2005;46:641\u20136.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"922_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","volume":"244","author":"R Tadayoni","year":"2021","unstructured":"Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244:93\u2013101.","journal-title":"Ophthalmologica"},{"key":"922_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/IAE.0000000000000749","volume":"36","author":"L He","year":"2016","unstructured":"He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina. 2016;36:492\u20138.","journal-title":"Retina"},{"key":"922_CR26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study. Ophthalmology. 2016;123:2213\u201324.","journal-title":"Ophthalmology"},{"key":"922_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics14020265","volume":"14","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Gorni G, Lanzetta P. Anti-VEGF drugs dynamics: relevance for clinical practice. Pharmaceutics. 2022;14:265.","journal-title":"Pharmaceutics"},{"key":"922_CR28","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761125s000lbl.pdf. Revised Oct 7, 2019. Accessed Nov 22, 2021."},{"key":"922_CR29","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125156s105lbl.pdf. Revised Oct 2014. Accessed Nov 22, 2021."},{"key":"922_CR30","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf. Revised Nov 2011. Accessed Nov 22, 2021"},{"key":"922_CR31","first-page":"1","volume":"20","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam\u2019s razor? Ocul Immunol Inflamm. 2021;20:1\u20133.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00922-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T03:30:06Z","timestamp":1655523006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00922-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00922-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Tanaka, None; H. Koizumi, None; T. Tamashiro, None; K. Itagaki, None; M. Nakayama, None; I. Maruko, None; S. Wakugawa, None; N. Terao, None; H. Onoe, None; Y. Wakatsuki, None; A. Kasai, None; M. Ogasawara, None; H. Shintake, None; Y. Sugano, None; A. Yamamoto, None; K. Kataoka, None; T. Hasegawa, None; T. Izumi, None; M. Kawai, None; R. Maruko, None; T. Sekiryu, None; A. A. Okada, None; T. Iida, None; R. Mori, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}